Adc Therapeutics Sa Stock Price, News & Analysis

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in two upcoming investor conferences. The company's CEO Ameet Mallik will present at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, from 10:30-10:55 a.m. ET, and at the Jefferies Global Healthcare Conference on June 5, 2025, from 9:55-10:25 a.m. ET. Both presentations will be in a fireside chat format and available via webcast on the company's investor relations website, with replays accessible for approximately 30 days after each event.

ADC Therapeutics (NYSE: ADCT) reported Q1 2025 financial results and operational updates. Key highlights include promising LOTIS-7 trial data showing ZYNLONTA® plus glofitamab achieved a 95.5% overall response rate and 90.9% complete response rate in r/r DLBCL patients. The company reached 40-patient enrollment in LOTIS-7 dose expansion arm and expects to provide updates in H2 2025. Financial results show $17.4M in ZYNLONTA product revenues and $5.6M in license revenues. Net loss was $38.6M ($0.36 per share), improved from $46.6M loss in Q1 2024. Cash position stands at $194.7M, expected to fund operations into H2 2026. The company discontinued the ADCT-602 trial for r/r B-cell acute lymphoblastic leukemia based on clinical data.

ADC Therapeutics (NYSE: ADCT) announced promising results from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with glofitamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The trial showed remarkable efficacy with an overall response rate of 95.5% and complete response rate of 90.9% among 22 evaluable patients. The study included 31 patients who received ≥1 ZYNLONTA dose, demonstrating a manageable safety profile. Key adverse events included neutropenia (32.3%) as the most common Grade ≥3 TEAE. The data will be presented at both the European Hematology Association 2025 Congress (EHA2025) in Milan and the 18th International Conference on Malignant Lymphoma (ICML) in Lugano.

The company will also present updated LOTIS-5 safety run-in data evaluating ZYNLONTA plus rituximab combination at EHA2025.

ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has scheduled its first quarter 2025 financial results conference call and webcast for May 14, 2025, at 8:30 a.m. EDT. The company will present financial results and provide business updates during the call.

Participants can join via toll-free dial-in (1-800-836-8184 for North America and Canada) or through a live webcast available on the company's investor relations website. Pre-registration is recommended 10 minutes before the event. The webcast recording will be accessible for 30 days after the call.

ADC Therapeutics (NYSE: ADCT) presented preclinical data for three exatecan-based antibody drug conjugates (ADCs) at the AACR Annual Meeting 2025. The key highlight was ADCT-242, targeting Claudin-6, which demonstrated potent antitumor activity in ovarian and non-small lung cancer models, with good tolerance up to 150 mg/kg in mice and 40 mg/kg in cynomolgus monkeys.

Additionally, ADCT-241, targeting PSMA, showed promising results in prostate cancer models with synergistic effects when combined with enzalutamide. The third ADC, HuB14-VA-PL2202, targeting ASCT2, exhibited potent antitumor activity in both solid and hematological cancer cell lines with good tolerability in preclinical studies.

ADC Therapeutics (NYSE: ADCT) has granted stock options to two new employees to purchase a total of 128,600 common shares, effective April 1, 2025. The grants, approved by the Company's Compensation Committee under the Inducement Plan, serve as material employment incentives.

The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly at 1/48th of the total shares, contingent on continued employment. The grants were made under NYSE's Listed Company Manual Rule 303A.08's employment inducement exemption.

ADC Therapeutics (NYSE: ADCT) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's CEO, Ameet Mallik, will deliver a company overview presentation on Tuesday, April 8, 2025, at 8:00 a.m. ET.

Investors and interested parties can access the live webcast through the Events & Presentations page in the Investors section of ADC Therapeutics' website at ir.adctherapeutics.com. A replay of the presentation will remain available for approximately 30 days following the event.

ADC Therapeutics (NYSE: ADCT) reported its Q4 and full year 2024 financial results. The company achieved significant milestones in its ZYNLONTA® clinical trials, with the LOTIS-7 Phase 1b trial showing 94% best ORR and 72% CR rate in combination with glofitamab. The LOTIS-5 Phase 3 confirmatory trial completed enrollment with data expected in late 2025.

Financial highlights include Q4 2024 net product revenues of $16.4M and full-year revenues of $69.3M from ZYNLONTA®. The company reported a Q4 net loss of $30.7M ($0.29 per share) and full-year net loss of $157.8M ($1.62 per share). Cash position stands at $250.9M as of December 31, 2024, providing runway into second half of 2026.

Operating expenses showed improvement with reduced R&D ($109.6M), S&M ($44.0M), and G&A ($41.9M) expenses compared to 2023.

ADC Therapeutics (NYSE: ADCT) announced the acceptance of multiple preclinical program abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago.

The presentations will feature:

• An oral presentation on ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6 for ovarian and non-small lung cancer
• A poster presentation on ADCT-241, targeting PSMA for prostate cancer treatment
• A poster presentation on HuB14-VA-PL2202, targeting ASCT2 for solid and hematological cancers

Chief Scientific Officer Patrick van Berkel highlighted these ADCs' potential for targeted cancer treatment in areas with unmet medical needs.